Tarsus Pharmaceuticals, Inc. TARS Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s stock-based comp?
- Tarsus Pharmaceuticals, Inc. (TARS) reported stock-based comp of $11.97M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s stock-based comp changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s stock-based comp increased by 72.7% year-over-year, from $6.93M to $11.97M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s stock-based comp has grown at a 49.0% compound annual growth rate (CAGR), from $8.46M to $41.72M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.